Conferences - Results from #180

Viewing 181-200 of 11532 articles

ASCO 2024: Final Results of CORE-001: A Phase-2, Single Arm Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in Patients with BCG-Unresponsive, Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ

ASCO 2024: Utility of ctDNA Burden as a Prognostic Biomarker for Efficacy in TALAPRO-2: A Phase 3 Study of Talazoparib + Enzalutamide Versus Placebo + Enzalutamide as First-Line Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO 2024: Comparison of TKI and CPI Strategies as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma: Real-World Outcome Data from the German Research Platform CARAT

ASCO 2024: Discovery of a Novel Non-Negative Matrix Factorization-Based Homologous Recombination Deficiency Score and Subsequent Exploration in TALAPRO-2

ASCO 2024: 68Ga-PSMA PET/CT Response and Clinical Outcomes in Patients Treated with Enzalutamide as First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer: Results of a Prospective Study

ASCO 2024: Lenvatinib plus Pembrolizumab vs Sunitinib in Advanced Renal Cell Carcinoma: Patterns of Progression and Subsequent Therapy in the CLEAR Trial

ASCO 2024: Changes in Treatment Patterns and Attrition Rates in Patients with Metastatic Clear Cell Renal Cell Carcinoma

ASCO 2024: CYP11A1 Inhibitor MK-5684 Versus Next-Generation Hormonal Agent Switch in Patients with Metastatic Castration-Resistant Prostate Cancer After One Prior Next-Generation Hormonal Agent: Phase 3 MK-5684-004 Study

ASCO 2024: A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy (RP) in Patients with Unfavorable Intermediate-Risk or High-Risk Prostate Cancer with BRCA1/2 Gene Alterations (NePtune)

ASCO 2024: Randomized PROSTATE-IQ Trial to Reduce ADT Treatment Burden for Patients with Biochemical Recurrence After Prostatectomy

ASCO 2024: Matched Tissue and Circulating Tumor DNA (ctDNA) Analysis in Renal Cell Carcinoma (RCC): Results from a Multimodal Real-World Database

ASCO 2024: Impact of Mental Health Illness Prior to Prostate Cancer Diagnosis on Treatment Received and Prostate Cancer Outcomes

ASCO 2024: ProstACT GLOBAL: A Phase 3 Study of Best Standard of Care with and Without 177Lu-DOTA-Rosopatamab (TLX591) for Patients with PSMA Expressing mCRPC Progressing Despite Prior Treatment with a Novel Androgen Axis Drug

ASCO 2024: Enfortumab Vedotin plus Pembrolizumab in the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology: A Phase II Study

ASCO 2024: Effect of Concomitant Medications on Treatment Response and Survival in Non-Metastatic Castrate Resistant Prostate Cancer: Secondary Analysis of the SPARTAN Trial

ASCO 2024: Association Between Prostate-Specific Antigen (PSA) Level 0.2 ng/mL and Risk of Radiological Progression in Patients with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): Follow-up Analysis of ARAMIS

ASCO 2024: Veterans Affairs Seamless Phase II/III Randomized Trial of Standard Systemic Therapy with or Without PET-Directed Local Therapy for Oligometastatic Prostate Cancer (VA STARPORT)

ASCO 2024: CYP11A1 Inhibitor MK-5684 Versus Next-Generation Hormonal Agent Switch in Patients with Metastatic Castration-Resistant Prostate Cancer After Next-Generation Hormonal Agent and Taxane-Based Chemotherapy: Phase 3 MK-5684-003 Trial

ASCO 2024: Harnessing the Immune System in Renal Cell Carcinoma: Current and Novel Immunotherapy Approaches

ASCO 2024: Discussion: Living Your Best Life on Treatment

5
6
7
8
9
10
11
12
13
14